| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT04831450) | University of Miami | 2022-07-01 |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (NCT04997902) | Kura Oncology, Inc. | 2021-12-07 |
| Artificial Intelligence in Functional Imaging for Individualized Treatment of Head and Neck Squamous Cell Carcinoma Patients (NCT05192655) | Charite University, Berlin, Germany | 2021-12-01 |
| Intratumoral Microdosing of Motolimod in HNSCC (NCT04272333) | Presage Biosciences | 2021-10-15 |
| Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (NCT04811027) | Immutep S.A.S. | 2021-08-27 |
| Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT04861467) | Chinese Academy of Medical Sciences | 2021-06-01 |
| Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy (NCT05337631) | University Hospital Freiburg | 2021-06-01 |
| Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy (NCT04892849) | University of Erlangen-Nürnberg Medical School | 2021-04-30 |
| Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC (NCT04340258) | University of Cincinnati | 2021-02-04 |
| A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer (NCT04722523) | Memorial Sloan Kettering Cancer Center | 2021-01-20 |
| A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation (NCT04141449) | Brigham and Women's Hospital | 2020-11-18 |
| Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) (NCT04606940) | University Health Network, Toronto | 2020-10-19 |
| A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (NCT04370587) | ImmVira Pharma Co. Ltd | 2020-09-17 |
| Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136) | Dan Zandberg | 2020-09-14 |
| A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors (NCT05602792) | ImmVira Pharma Co. Ltd | 2020-04-21 |
| COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies (NCT04354246) | Compugen Ltd | 2020-03-31 |
| Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (NCT04042935) | University of Colorado, Denver | 2020-02-27 |
| Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors (NCT04157985) | Dan Zandberg | 2019-11-15 |
| De-Escalation Therapy for Human Papillomavirus Negative Disease (NCT03944915) | University of Chicago | 2019-08-26 |
| Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN (NCT03726775) | Groupe Oncologie Radiotherapie Tete et Cou | 2019-07-17 |
| Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) (NCT04279509) | National University Hospital, Singapore | 2019-05-29 |
| Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (NCT03719690) | Kura Oncology, Inc. | 2019-03-15 |
| Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (NCT03625323) | Immutep S.A.S. | 2019-02-21 |
| Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations (NCT03740100) | M.D. Anderson Cancer Center | 2019-01-25 |
| Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT03480672) | University of Leipzig | 2018-08-06 |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (NCT03526835) | Merus B.V. | 2018-05-02 |
| Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma (NCT03652142) | Attikon Hospital | 2018-05-01 |
| WGA in Platinum-refractory HNSCC Underwent Nivolumab (NCT03917537) | Chang Gung Memorial Hospital | 2018-04-01 |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma (NCT03422536) | University of Arizona | 2017-12-05 |
| Dose-Effect Relation of Salivary Gland Irradiation (NCT03367780) | The Netherlands Cancer Institute | 2017-11-21 |
| A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy (NCT03356587) | Seoul National University Hospital | 2017-10-16 |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) (NCT02999087) | Groupe Oncologie Radiotherapie Tete et Cou | 2017-09-14 |
| Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] (NCT03292250) | Seoul National University Hospital | 2017-09-10 |
| Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma (NCT06446570) | Seoul National University Hospital | 2017-09-10 |
| Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (NCT03107182) | University of Chicago | 2017-06-27 |
| Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer (NCT03182959) | University of Arizona | 2017-04-24 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma (NCT03082534) | University of California, San Diego | 2017-03-28 |
| Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) (NCT02998385) | Groupe Oncologie Radiotherapie Tete et Cou | 2017-01-20 |
| Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (NCT02433626) | Critical Outcome Technologies Inc. | 2015-12-01 |
| Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (NCT02216617) | Groupe Oncologie Radiotherapie Tete et Cou | 2014-08-06 |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (NCT00609284) | Groupe Oncologie Radiotherapie Tete et Cou | 2008-02-15 |